Clinical trials
Central Nervous System Diseases clinical trials
Below are recruiting central nervous system diseases clinical trials, each written for real people, not researchers. We’re tracking 207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT07355218RecruitingPhase 3
Testing enpatoran for lupus skin problems
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Upland, CaliforniaAges 18–75 - NCT06647069RecruitingPhase 1
Testing a new drug for lupus and rheumatoid arthritis
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Brisbane, QueenslandAges 18–75 - NCT06739993Recruiting
Can breathing exercises improve blood sugar in prediabetes?
This study tests if a special breathing technique (heart rate variability biofeedback) can help people with prediabetes improve their blood sugar control. You will attend screening visits and practice breathing exercises at home to see if this lowers your risk of developing diabetes.
Mainz, MainzAges 18–65 - NCT06787560RecruitingEarly Phase 1
CAR-T cells and stem cell transplant for blood diseases
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Hangzhou, ZhejiangAges Any age - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT03872102Recruiting
Brain imaging study to track Parkinson-related disease changes
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
Dallas, TexasAges Any age - NCT07570212Recruiting
Personalized Brain Stimulation for Parkinson's and Similar Disorders
This study tests whether customized transcranial magnetic stimulation (a non-invasive technique that uses magnetic pulses to stimulate brain activity) can help improve symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. The treatment is tailored to each person's brain activity patterns.
Beijing, Beijing MunicipalityAges 30–80 - NCT07178210Recruiting
Robotic surgery for Alzheimer's disease
This trial tests a new robotic surgery that connects tiny lymph vessels in the head and neck to see if it can help people with Alzheimer's disease. It may improve how the brain clears waste and could slow symptoms.
Palo Alto, CaliforniaAges 50 years+ - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT07640542RecruitingEarly Phase 1
Brain imaging study for Parkinson's and MSA patients
This early-stage research trial tests a new brain-imaging tracer called [11C]MODAG-005 to help doctors better understand Parkinson's disease (PD) and multiple system atrophy (MSA). You would undergo PET/CT and MRI scans twice, a few weeks apart, to see how reliable the imaging is.
Tübingen, Baden-WurttembergAges 50–75 - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT05369195Recruiting
Protecting the brain during a heart procedure for atrial fibrillation
This trial studies a way to help protect the brain during a catheter procedure that closes the left atrial appendage (a small heart pouch) in people with atrial fibrillation. It may help lower the risk of stroke-related brain injury for patients who can’t safely take blood thinners.
KatowiceAges 18 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07382674Recruiting
Exercise program for older adults with Parkinson's
This trial tests a fun exercise system designed for older adults with mild to moderate Parkinson's disease. It aims to help improve movement and well-being through engaging physical activities.
Atlanta, GeorgiaAges 40 years+ - NCT06851091Recruiting
Fibromyalgia study on pain sensitivity and balance
This study looks at how fibromyalgia affects your sensitivity to pain and your sense of balance. It may help find better ways to treat these symptoms.
Istanbul, ÜsküdarAges 18–65 - NCT06959628Recruiting
Study of a new shunt system for carotid artery blockage treatment
This trial tests a special shunt system to protect your brain during carotid artery stenting. It may help people with severe blockages in the neck artery that supplies blood to the brain.
BeijingAges 18 years+
Hear when a new Central Nervous System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for central nervous system diseases?
- Yes. Clin2 currently lists 207 recruiting central nervous system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a central nervous system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a central nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.